Indoco Remedies Q1 FY27 Earnings Call — Analysis (NSE: INDOCO)
Indoco Remedies reports 8.2% consolidated revenue growth and significant margin recovery in Q1FY27, but flat domestic formulations and USFDA overhang temper the outlook.
The take
Q1FY27 Consolidated Revenue ₹466.2 Cr ( +8.2% YoY ) . New guidance — consolidated revenue growth tar… 12-15% CAGR . New story: Margin recovery and cost efficiency .
Results
Consolidated revenue ₹466.2 Cr +8.2% YoY; standalone EBITDA margin improved sharply to 10.3% from 3.8% YoY, though domestic formulations were flat at ₹204 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Standalone Revenue | ₹408.1 Cr | +5.8% | yoy · Q1FY27 |
| Consolidated Revenue | ₹466.2 Cr | +8.2% | yoy · Q1FY27 |
| Standalone EBITDA | ₹42.2 Cr | yoy · Q1FY27 | |
| Standalone EBITDA Margin | 10.3% | yoy · Q1FY27 · 3.8% in Q1FY26 | |
| Consolidated EBITDA | ₹41.0 Cr | yoy · Q1FY27 | |
| Consolidated EBITDA Margin | 8.8% | yoy · Q1FY27 · 4.1% in Q1FY26 | |
| Domestic Formulation Revenue | ₹204.0 Cr | yoy · Q1FY27 | |
| International Formulation Revenue | ₹145.1 Cr | +2.8% | yoy · Q1FY27 |
| US Revenue | ₹45.9 Cr | +62.2% | yoy · Q1FY27 |
| Europe Revenue | ₹65.0 Cr | +2.5% | yoy · Q1FY27 |
| Emerging Markets Revenue | ₹31.7 Cr | yoy · Q1FY27 · ₹46.1 Cr in Q1FY26 | |
| API Revenue | ₹52.1 Cr | +42.4% | yoy · Q1FY27 |
| CRO/Analytical Revenue | ₹6.9 Cr | +36.2% | yoy · Q1FY27 |
| Total Debt | ₹930 Cr | point_in_time · Q1FY27 · Jun-26 | |
| Average Interest Rate | ~9% | none · Q1FY27 |
Guidance
Management aims for double-digit EBITDA margins in FY27 and targets 12–15% overall sales CAGR over the next few years.
What management committed to
- Indoco is aiming for double-digit EBITDA margins for FY27. — double-digit, FY27
- Indoco is directly in line for doubling [its] export business in 2 to 3 years. — doubling, FY29
- Management expects [emerging markets] primaries to rebound immediately in the second quarter (Q2FY27). — rebound, Q2FY27
- The impact of [2 percentage-point COGS increase from raw material price rise] will partly continue into Q3FY27, after which [gross margins] should normalize. — normalize, Q3FY27
- Indoco will see some improvement in API sales coming out of the ORIC facility [Warren] from probably Q4 this year (Q4FY27). — improvement, Q4FY27
- Total capex for FY27 will not exceed ₹50 Cr, and likely not even ₹40 Cr, largely maintenance capex. — not more than ₹50 Cr, FY27
- Indoco will repay ₹110 Cr of debt in FY27 and another ₹150 Cr in FY28, totaling ₹260 Cr reduction in about 7 to 18 months. — ₹110 Cr (FY27) and ₹150 Cr (FY28), FY28
- Overall, Indoco will target 12% to 15% sales CAGR over the next few years. — 12-15% CAGR, over the next few years
Key themes
Margin recovery, exports doubling ambition, and USFDA uncertainty
How the narrative shifted
- Margin recovery and cost efficiency: Management credits structural efficiencies from the Master Manufacturing Plan, citing 26% fewer batches and headcount reduction, which drove sharp YoY margin improvement.
- Export doubling ambition: Management reiterates that they are in line to double export business in 2-3 years, supported by strong order book and API growth, despite near-term quarterly fluctuations.
- USFDA sterile plant overhang: The sterile injectable plant awaits FDA audit with no timeline; management signals frustration and hints at contingency plans, limiting visibility on high-value US ophthalmic launches.
- Domestic brand scaling: Top brands like Cyclopam near ₹200 Cr and midsized brands show 86% aggregate growth, driving confidence in sustainable high single-digit to double-digit domestic growth.
- Working capital and debt discipline: Cash flow pressures from prior quarters have been largely resolved; management commits to scheduled debt repayments and uses ophthalmic divestment proceeds to deleverage.
- Emerging markets temporary dip: War-related product availability and freight issues, along with quarter-end billing patterns, caused a one-off decline in emerging markets; management expects a quick rebound.
Operational commentary
- Baddi Unit I successfully completed Malta Medicines Authority audit; Baddi Unit III received EU-GMP certification from German Health Authority, Berlin.
- Goa Plant I cleared Malta Medicines Authority audit; facility holds EU-GMP certification.
- Indoco Stability Centre (IAS) at Aurangabad successfully completed USFDA pre-approval inspection with zero observations.
- Top 5 domestic brands contribute 42% of domestic portfolio; Cyclopam nearing ₹200 Cr landmark mega brand with 44% absolute growth since 2022.
- Midsized brands (SM Fibro, Rexidin-M, Oxipod CV, Dropizin) recorded aggregate 86% growth; Dropizin achieved 3x breakout to ₹14 Cr.
- Divestment of Ophthalmic Division in India and Africa sharpens focus on core therapeutic areas.
- Field force reaches over 242,000 prescribing doctors; company holds 33rd rank in Indian pharma market and 20th in prescription volume.
- Master Manufacturing Plan delivering efficiency: 26% fewer batches manufactured YoY to achieve comparable output; headcount reduced by ~900 people in operations.
- Ophthalmic division proceeds partly used for debt repayment; total debt reduced by ₹34 Cr to ₹930 Cr.
- US subsidiary turned profitable this quarter; sterile injectable plant awaiting USFDA audit.
- Order book in excess of ₹250 Cr for international execution; capacity utilization at 70–80% across key plants on single shift.
Analyst Q&A
Q. Any update from the USFDA about the plant?
No, we've not heard anything yet, but let's keep our fingers crossed, hopefully in the next couple of months.
Q. Request to share FPP revenue/profitability and warrant breakup
Okay. We'll send this information. We'll send this information.
Research and educational content only. Not investment advice.